Texas Children's Hospital Infusion Center
Welcome,         Profile    Billing    Logout  
 0 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Satter, Lisa Forbes
NCT05438407 / 2022-001624-14: Pediatric Patients Aged 4 to 11 Years with APDS

Active, not recruiting
3
15
Europe, Japan, US
Leniolisib
Pharming Technologies B.V., CMIC Co, Ltd. Japan, Labcorp Central Laboratory, Fortrea, Aixial Group
APDS
07/25
12/25
NCT05693129: Pediatric Patients Aged 1 to 6 Years with APDS

Recruiting
3
15
Europe, Japan, US
Leniolisib
Pharming Technologies B.V., CMIC Co, Ltd. Japan, Labcorp Central Laboratory, Fortrea, Aixial Group
APDS
09/25
02/26
NCT03906318: Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia

No Longer Available
N/A
NA
Iticitinib
Incyte Corporation
Aplastic Anemia
 
 
NCT05561985: Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease

Available
N/A
NA
Itacitinib, INCB039110
Incyte Corporation
STAT1 Gain-of-Function Disease
 
 
Forbes-Satter, Lisa
NCT03113760 / 2018-003297-27: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

Completed
3
15
Europe, Canada, US
Tadekinig alfa, IL-18BP, r-hIL-18BP, 0.9% sodium chloride
AB2 Bio Ltd.
NLRC4-MAS, XIAP Deficiency
10/23
11/23
NCT05693129: Pediatric Patients Aged 1 to 6 Years with APDS

Recruiting
3
15
Europe, Japan, US
Leniolisib
Pharming Technologies B.V., CMIC Co, Ltd. Japan, Labcorp Central Laboratory, Fortrea, Aixial Group
APDS
09/25
02/26
Alas, Eugenia
NCT05438407 / 2022-001624-14: Pediatric Patients Aged 4 to 11 Years with APDS

Active, not recruiting
3
15
Europe, Japan, US
Leniolisib
Pharming Technologies B.V., CMIC Co, Ltd. Japan, Labcorp Central Laboratory, Fortrea, Aixial Group
APDS
07/25
12/25
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Recruiting
3
348
Europe, Canada, Japan, US, RoW
Remibrutinib, Placebo
Novartis Pharmaceuticals
Chronic Inducible Urticaria
07/26
12/28

Download Options